Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Last trade$3.78
Day change-$10.32 (-73.19%)
Day range$3.39 – $13.75
Volume2,232,839
Market cap$102M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$102.43M
Price / earnings
—
Price / book
44.34×
Price / sales
2.72×
EV / sales
2.28×
EV / EBITDA
-0.88×
Profitability
Earnings per share
-$22.59
Return on assets
-534.43%
Return on equity
-7,104.24%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.42×
Current ratio
1.25×
Quick ratio
1.25×
Cash ratio
0.82×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$50.17M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CUE, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$7.88M
$5.69M
$21.94M
$2.15M
$2.95M
$421K
$1.58M
$3.34M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$7.88M
$5.69M
$21.94M
$2.15M
$2.95M
$421K
$1.58M
$3.34M
Selling, general and administrative
$46.57M
$4.15M
$3.45M
$4.94M
$3.68M
$4.17M
$4.02M
$2.87M
Research and development
$49.01M
$6.9M
$16.53M
$4.75M
$7.91M
$8.55M
$7.18M
$9.38M
Total operating expenses
$95.57M
$11.04M
$19.98M
$9.69M
$11.59M
$12.72M
$11.21M
$12.25M
Operating income
-$87.7M
-$5.35M
$1.96M
-$7.54M
-$8.64M
-$12.3M
-$9.63M
-$8.91M
Interest expense
-$5K
$0
-$51K
-$75K
-$45K
$0
-$153K
-$188K
Income before taxes
-$153.07M
-$5.18M
$2.09M
-$7.45M
-$8.48M
-$12.26M
-$9.5M
-$8.66M
Income taxes
$0
$0
$500K
$0
$0
$0
$0
$0
Net income
-$153.07M
-$5.18M
$1.59M
-$7.45M
-$8.48M
-$12.26M
-$9.5M
-$8.66M
Net income attributable to common shareholders
-$153.07M
-$5.18M
$1.59M
-$7.45M
-$8.48M
-$12.26M
-$9.5M
-$8.66M
EBITDA
-$87.66M
-$4.8M
$2.64M
-$7.46M
-$8.54M
-$12.2M
-$9.53M
-$8.81M
Basic earnings per share
-$24.14
-$1.08
$0.44
-$2.10
-$2.67
-$4.95
-$3.83
-$5.10
Diluted earnings per share
-$24.14
-$1.08
$0.44
-$2.10
-$2.67
-$4.95
-$3.83
-$5.10
Recent news
Company coverage with links to the original publishers.
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.
Lift Therapeutics announced the appointment of Daniel Passeri as CEO, bringing over 30 years of oncology drug development experience. Bo Rode Hansen transitions from Interim CEO to President and Board member. The company is preparing to advance its lead immuno-Modulatory Alpha Neutrophil (iMAN) program into first-in-human clinical studies in early 2027.
The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the highest revenue. Multiple companies are advancing innovative therapies targeting HPV16-positive HNSCC and other molecular pathways.
Cue Biopharma secured $50 million in funding through a private placement led by Cormorant Asset Management and Columbia Threadneedle Investments. The company will use proceeds to advance clinical development of its immunological disorder therapies, including Phase 2 data expected from a CSU study in China by Q3 2026.
Cue Biopharma granted inducement equity awards to seven new employees on May 3, 2026, including newly appointed President and CEO Shao-Lee Lin, M.D., Ph.D. Dr. Lin received stock options for 655,074 shares and 327,537 restricted stock units, while six other new employees received aggregate options for 518,599 shares and 327,534 RSUs, all at an exercise price of $30.42 per share.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.